NeuroPace: Neurostimulator for Epilepsy Offers Revenue Opportunity of $3.5 Billion!
Reading Time: 2 minutes
The medical technology company NeuoPace (NPCE) specializes in implantable neurostimulators aimed at reducing and preventing epilepsy in medication-resistant patients. The Responsive Neurostimulation System (RNS) has already been used in over 8,000 patients since its FDA approval in 2023, creating one of the world's largest proprietary iEEG databases with over 24 million recordings. This is one reason why the median seizure reduction of 82% over three years surpasses competing products. While 3.4 million Americans have already received an epilepsy...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
